NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis $28.12 -0.20 (-0.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.09▼$29.1250-Day Range$18.31▼$28.3252-Week Range$11.25▼$53.77Volume412,324 shsAverage Volume1.06 million shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$41.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside46.2% Upside$41.13 Price TargetShort InterestBearish9.83% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.58Based on 7 Articles This WeekInsider TradingSelling Shares$5.42 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.82) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector204th out of 936 stocksPharmaceutical Preparations Industry86th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akero Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.83% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 3.1 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Akero Therapeutics this week, compared to 6 articles on an average week.Search Interest2 people have searched for AKRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,419,376.00 in company stock.Percentage Held by InsidersOnly 7.94% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -8.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -8.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesJuly 26 at 6:18 AM | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $3,752,459.34 in StockJuly 19, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $976,100.44 in StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 3, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 5,000 SharesJuly 26 at 6:13 PM | investing.comAkero Therapeutics Inc (AKRO)July 20, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 34,811 SharesJuly 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)June 28, 2024 | globenewswire.comLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 25, 2024 | businesswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 25, 2024 | prnewswire.comAKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitJune 24, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)June 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROJune 24, 2024 | globenewswire.comAKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKROJune 24, 2024 | globenewswire.comLowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmJune 24, 2024 | businesswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 23, 2024 | globenewswire.comTUESDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKROJune 23, 2024 | globenewswire.comDeadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)See More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$41.13 High Stock Price Target$56.00 Low Stock Price Target$30.00 Potential Upside/Downside+46.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.72% Return on Assets-25.63% Debt Debt-to-Equity Ratio0.04 Current Ratio30.12 Quick Ratio30.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book2.93Miscellaneous Outstanding Shares69,150,000Free Float63,660,000Market Cap$1.94 billion OptionableOptionable Beta-0.28 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.04MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $672.35kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $722.32kMr. William R. White J.D. (Age 51)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $678.06kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $678.06kMr. Scott A. Gangloff (Age 50)Chief Technical Officer Mr. David West J.D.Vice President of LegalMr. John J. Schembri (Age 62)Vice President & Head of Finance Mr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy More ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOEnanta PharmaceuticalsNASDAQ:ENTACymaBay TherapeuticsNASDAQ:CBAYSummit TherapeuticsNASDAQ:SMMTElanco Animal HealthNYSE:ELANView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 61,988 shares on 7/26/2024Ownership: 0.363%William Richard WhiteSold 139,083 sharesTotal: $3.75 M ($26.98/share)William Richard WhiteSold 34,811 sharesTotal: $976,100.44 ($28.04/share)SG Americas Securities LLCBought 9,532 shares on 7/12/2024Ownership: 0.021%Bourgeon Capital Management LLCSold 6,450 shares on 7/11/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions How have AKRO shares performed this year? Akero Therapeutics' stock was trading at $23.35 at the beginning of the year. Since then, AKRO shares have increased by 20.4% and is now trading at $28.12. View the best growth stocks for 2024 here. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings data on Friday, May, 10th. The company reported ($0.90) EPS for the quarter, hitting analysts' consensus estimates of ($0.90). When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.36%), SG Americas Securities LLC (0.02%), Bourgeon Capital Management LLC (0.01%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy and Tomas J Heyman. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB) and Alector (ALEC). This page (NASDAQ:AKRO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
